Skip to main content
. 2017 Jun 9;8(58):97890–97899. doi: 10.18632/oncotarget.18426

Figure 2. PFS of first-line and second-line treatments.

Figure 2

(A) Median PFS for the first-line treatment; (B) Median PFS for the second-line treatment. PFS, progression-free survival; arm A: mFOLFIRI; arm B: mFOLFOX7.